WO2009010968A3 - Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs - Google Patents

Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs Download PDF

Info

Publication number
WO2009010968A3
WO2009010968A3 PCT/IL2008/000977 IL2008000977W WO2009010968A3 WO 2009010968 A3 WO2009010968 A3 WO 2009010968A3 IL 2008000977 W IL2008000977 W IL 2008000977W WO 2009010968 A3 WO2009010968 A3 WO 2009010968A3
Authority
WO
WIPO (PCT)
Prior art keywords
cathelicidin
inhibitors
disease
endogenous
disease treatment
Prior art date
Application number
PCT/IL2008/000977
Other languages
English (en)
Other versions
WO2009010968A2 (fr
Inventor
Yitzchak Hillman
Original Assignee
Yitzchak Hillman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL184611A external-priority patent/IL184611A0/en
Priority claimed from IL187627A external-priority patent/IL187627A0/en
Application filed by Yitzchak Hillman filed Critical Yitzchak Hillman
Priority to AU2008277257A priority Critical patent/AU2008277257B2/en
Priority to JP2010516648A priority patent/JP2010533705A/ja
Priority to CA2696833A priority patent/CA2696833A1/fr
Priority to EP08776610A priority patent/EP2200628A2/fr
Publication of WO2009010968A2 publication Critical patent/WO2009010968A2/fr
Publication of WO2009010968A3 publication Critical patent/WO2009010968A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

La présente invention concerne des procédés permettant de traiter une maladie et d'accélérer la cicatrisation, qui consistent à obtenir une quantité thérapeutiquement efficace d'un peptide antimicrobien mammalien (PAM) ou d'un analogue de celui-ci, en particulier une cathélicidine ou un fragment de cathélicidine ou un analogue de cathélicidine, et de traiter de ce fait la maladie chez le sujet nécessitant le traitement. L'invention concerne également des analogues ou des fragments spécifiques de cathélicidine qui agissent en tant qu'agonistes, ainsi que le font les cathélicidines endogènes, ou en tant que dominants négatifs ou en tant qu'inhibiteurs de cathélicidine endogène ou de tout autre AMP endogène, ou qui font concurrence à des agents pro-inflammatoires ou des fragments d'AMP sur des récepteurs de même origine sans induire une maladie.
PCT/IL2008/000977 2007-07-15 2008-07-15 Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs WO2009010968A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2008277257A AU2008277257B2 (en) 2007-07-15 2008-07-15 Disease treatment via antimicrobial peptides or their inhibitors
JP2010516648A JP2010533705A (ja) 2007-07-15 2008-07-15 抗菌ペプチドまたはその阻害剤を用いた疾病治療
CA2696833A CA2696833A1 (fr) 2007-07-15 2008-07-15 Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs
EP08776610A EP2200628A2 (fr) 2007-07-15 2008-07-15 Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL184611A IL184611A0 (en) 2007-07-15 2007-07-15 Disease treatment via antimicrobial peptides or their inhibitors
IL184611 2007-07-15
IL187627A IL187627A0 (en) 2007-11-26 2007-11-26 Disease treatment via antimicrobial peptides or their inhibitors
IL187627 2007-11-26

Publications (2)

Publication Number Publication Date
WO2009010968A2 WO2009010968A2 (fr) 2009-01-22
WO2009010968A3 true WO2009010968A3 (fr) 2009-05-28

Family

ID=39944436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/000977 WO2009010968A2 (fr) 2007-07-15 2008-07-15 Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs

Country Status (5)

Country Link
EP (1) EP2200628A2 (fr)
JP (2) JP2010533705A (fr)
AU (1) AU2008277257B2 (fr)
CA (1) CA2696833A1 (fr)
WO (1) WO2009010968A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0621148A2 (pt) * 2005-12-29 2011-11-29 Univ Kansas State polipeptìdeo purificado, moléculas de ácido nucléico isolada, célula isolada, método para produzir um polipeptìdeo, composição, métodos para inibir o crescimento microbiano, artigo manufaturado e anticorpo purificado
CA2699035A1 (fr) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Utilisation du peptide c de l'insuline, seul ou en combinaison avec glp-1, en tant qu'agent therapeutique
EP2197462A2 (fr) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Utilisation d'un peptide du recepteur de il-1, seule ou en combinaison avec un ester d-ala-gln-octadecyl, en tant qu'agent thérapeutique
US20130034568A1 (en) * 2010-01-22 2013-02-07 Georgios Hajishengallis Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130123201A1 (en) * 2010-02-25 2013-05-16 University Of Manitoba Modulation of cytokine-induced chronic inflammatory responses
CA2948455C (fr) 2014-05-09 2023-09-19 Universiteit Utrecht Holding B.V. Nouveaux derives de cath2
DE202014007548U1 (de) 2014-09-16 2014-12-02 Pegasor Oy Vorrichtung zur Spülung einer Partikelmessvorrichtung
WO2017098474A1 (fr) 2015-12-09 2017-06-15 Universidade Do Minho Formulations à base d'acide hyaluronique chargé de peptide antimicrobien, leur procédé de production et leurs utilisations
CN108570103B (zh) * 2018-04-03 2019-07-30 东北农业大学 一种富含色氨酸抗菌肽wk12及其制备方法和应用
CN111375051A (zh) * 2018-12-29 2020-07-07 江苏吉锐生物技术有限公司 一种多肽在制备预防和治疗人乳头瘤病毒感染制剂的应用
KR102475936B1 (ko) * 2020-10-15 2022-12-09 코스맥스 주식회사 펩타이드 ll-37을 발현하는 효모를 포함하는 화장료 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056307A2 (fr) * 2002-12-19 2004-07-08 Yitzchak Hillman Traitement de maladie par le biais d'inhibiteurs de peptides antimicrobiens
WO2004067025A1 (fr) * 2003-01-29 2004-08-12 Lipopeptide Ab Utilisation de la cathelicidine ll-37 et de derives associes pour une cicatrisation de plaie
WO2005040201A1 (fr) * 2003-10-21 2005-05-06 The Regents Of The University Of California Peptides humains antimicrobiens de cathelicidine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
GB1585061A (en) 1977-03-15 1981-02-25 Nat Res Dev Synthesis of peptides
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (fr) 1988-12-20 2000-02-15 Donald J. Kessler Methode pour obtenir des oligonucleotides synthetiques qui se lient specifiquement a des sites cibles sur des molecules d'adn double brin, en formant un triplex colineaire; methode d'utilisation de ces oligonucleotides synthetiques
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
AU784063B2 (en) 1999-09-22 2006-01-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Utilization of FPRL1 as a functional receptor by serum amyloid A (SAA)
US20030120037A1 (en) 1999-09-22 2003-06-26 Ji Ming Wang Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
US20020164685A1 (en) 2000-01-31 2002-11-07 Rosen Craig A. Nucleic acids, proteins, and antibodies
DE10029167B8 (de) 2000-06-19 2015-07-02 Leica Microsystems Cms Gmbh Verfahren und Vorrichtung zur Temperaturstabilisierung optischer Bauteile
US20020072495A1 (en) 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
US6610472B1 (en) 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
JP2002288642A (ja) 2001-03-27 2002-10-04 Nec Corp 掌紋部位分割装置とその掌紋部位分割方法、及び掌紋部位分割プログラム
US6839808B2 (en) 2001-07-06 2005-01-04 Juniper Networks, Inc. Processing cluster having multiple compute engines and shared tier one caches

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056307A2 (fr) * 2002-12-19 2004-07-08 Yitzchak Hillman Traitement de maladie par le biais d'inhibiteurs de peptides antimicrobiens
WO2004067025A1 (fr) * 2003-01-29 2004-08-12 Lipopeptide Ab Utilisation de la cathelicidine ll-37 et de derives associes pour une cicatrisation de plaie
WO2005040201A1 (fr) * 2003-10-21 2005-05-06 The Regents Of The University Of California Peptides humains antimicrobiens de cathelicidine

Also Published As

Publication number Publication date
AU2008277257B2 (en) 2014-03-06
EP2200628A2 (fr) 2010-06-30
CA2696833A1 (fr) 2009-01-22
WO2009010968A2 (fr) 2009-01-22
JP5860937B2 (ja) 2016-02-16
AU2008277257A1 (en) 2009-01-22
JP2010533705A (ja) 2010-10-28
JP2015028022A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
WO2009010968A3 (fr) Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
TW200744642A (en) Novel peptides for use in the treatment of obesity
WO2009025196A1 (fr) Peptide foxm1 et agent médicinal le comprenant
TW200630327A (en) Substituted phenylalkanoic acids
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
EP3533461A3 (fr) Peptides dérivés de prame et compositions immunogènes les comportant
EP2308841A3 (fr) Analogues de phlorizine comme inhibiteurs de SGLT2
NO20054769D0 (no) Substituerte fenylalkansyrer
NO20083793L (no) Antistoffer mot amyloid-beta peptid
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
WO2005072277A3 (fr) Fragments amides de l'hormone parathyroide et leurs applications
TN2012000393A1 (en) Agonist dr5 binding polypeptides
UA103526C2 (ru) Воспроизведенный сурфактант, который содержит аналоги белков естественных сурфактантов sp-b и sp-c
WO2007111661A3 (fr) anticorps humains specifiques a des matieres et des procedes a base de gastrine
CL2008003545A1 (es) Compuestos derivados del acido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonico; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de una resorcion osea excesiva o inapropiada o de una enfermedad causada por una prenilacion excesiva de proteinas objetivo.
WO2006137938A3 (fr) Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
WO2001080894A3 (fr) Utilisation d'antagonistes ou d'agonistes du recepteur retinoide dans le traitement de pathologies des cartilages et os

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776610

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2696833

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010516648

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008776610

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 983/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008277257

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008277257

Country of ref document: AU

Date of ref document: 20080715

Kind code of ref document: A